News 2023-09-20
Porton Gets Improved in the 2023 S&P Global ESG Score
Porton Pharma Solutions Ltd. is glad to announce that it scored 38 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment reflecting an improvement of 9 points based on the 2023 methodology over the last year, where scores in all the three dimensions getting improved and exceeding the industry average. (CSA Score as of 25/08/2023).
Porton continues to gain ground in its environmental, social, and governance initiatives. In 2023, Porton establishes a top-down ESG governance structure, which includes Board Strategy and ESG Committee, ESG Executive Committee and ESG Working Team, to ensure the implementation of responsibilities and management measures. Meanwhile, Porton has identified 19 ESG high material issues and will further address and respond to these issues and enhance ESG performance.
|
Governance |
Social |
Environmental |
|
Business ethics Operational compliance |
R&D and innovation IP protection Product quality and safety Customer service Data and information security Digitalization Diversity, equity and inclusion Occupational health and safety Human capital development Supply chain security Access to healthcare and wellbeing Green chemistry Community communication and development |
Environmental policy and management systems Wastewater management Waste management Climate change |
For Porton, improving ESG governance and performance is a continuous evolutionary process. We will always be committed to cooperating with all stakeholders to achieve sustainable development.
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
